King Luther Capital Management Corp Increases Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

King Luther Capital Management Corp grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 19.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,540 shares of the company's stock after purchasing an additional 3,324 shares during the period. King Luther Capital Management Corp owned about 0.07% of Medpace worth $6,824,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in MEDP. State Street Corp increased its stake in Medpace by 7.2% during the 3rd quarter. State Street Corp now owns 752,957 shares of the company's stock worth $251,337,000 after buying an additional 50,312 shares during the period. Geode Capital Management LLC grew its stake in shares of Medpace by 7.6% in the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company's stock worth $209,885,000 after acquiring an additional 44,371 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock worth $138,612,000 after acquiring an additional 109,886 shares during the period. American Capital Management Inc. raised its stake in shares of Medpace by 2.6% in the third quarter. American Capital Management Inc. now owns 380,646 shares of the company's stock valued at $127,060,000 after acquiring an additional 9,592 shares in the last quarter. Finally, GW&K Investment Management LLC boosted its holdings in Medpace by 93.9% in the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock valued at $91,516,000 after purchasing an additional 133,379 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Stock Down 3.4 %

MEDP stock opened at $325.87 on Wednesday. The business has a 50 day moving average price of $341.06 and a 200 day moving average price of $342.12. The stock has a market cap of $9.93 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77.

Remove Ads

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analysts Set New Price Targets

Separately, Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.